Fibrobiologics (FBLG)
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffer...
- Open
- 1.730
- High
- 1.900
- Low
- 1.710
- Prev. Close
- 1.760
- Volume
- 210.46K
- Turnover
- 379.27K
- Avg Price
- 1.802
- Bid/Ask Ratio
- --
- Amplitude
- 10.80%
- 52wk High
- 12.400
- Volume Ratio
- 2.15
- Turnover Ratio
- 5.34%
Fibrobiologics Analyst Rating
View moreForecast & Rating
Aug 4, 2026Price forecast
$12.50590.61%
Forecast & RatingBuy
2analysts
- Strong buy50.00%
- Buy0.00%
- Hold50.00%
- Sell0.00%
- Strong sell0.00%
News
- Weekly Review · 1 day ago, 06:46 AM
Weekly Recap | Fibrobiologics +25.69%, patent-fueled rally settles at $1.81
- PUBT · Sep 3 at 12:31 PM
FibroBiologics wins new US patent covering topical fibroblast-based wound healing therapy
- StockTitan · Sep 3 at 04:30 AM
FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing | FBLG Stock News
- PUBT · Sep 1 at 11:18 PM
FibroBiologics files Form 3 for director Leigh Steinberg
- PUBT · Sep 1 at 12:30 PM
FibroBiologics wins new US patent for degenerative disc disease treatment using fibroblast conditioned media
- PUBT · Aug 27 at 12:30 PM
FibroBiologics ships third CYWC628 batch to Australia for Phase 1/2 diabetic foot ulcer trial
